NEWARK, CA / ACCESS Newswire / May 28, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer ...

Takeda's $300 million wager on Protagonist Therapeutics' rusfertide for rare blood cancer polycythaemia vera (PV) appears to have paid off. The first phase 3 trial of the injectable hepcidin mimetic, ...

Longer term, their pipeline has another second growth wave through mezagitamab, elritercept, fazirsiran, TAK-928, and TAK-921 ...

Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The Company delivered solid results in line with its latest FY2025 Management ...

ICOTYDE™ (icotrokinra) approved by FDA in March for moderate-to-severe plaque psoriasis, triggering a $50 million milestone payment; Protagonist receives tiered royalties of 6% to 10% and is eligible ...

With a new CEO prepared to take the reins next month and three key launches on deck for 2026 and 2027, Takeda is ready to shake off the generic-related declines that have plagued revenues in recent ...

Massachusetts' largest life sciences employer just confirmed thousands of job cuts are coming — and hundreds in Cambridge are already on the clock.

Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut Takeda Pharmaceutical (NYSE:TAK) reported fiscal 2025 results that management described as solid despite pressure from generic ...

Detailed price information for Takeda Pharmaceutical Ltd ADR (TAK-N) from The Globe and Mail including charting and trades.

By Sahil Pandey and Siddhi Mahatole May 13 (Reuters) - Japan's Takeda Pharmaceutical plans to cut about 4,500 jobs in fiscal year 2026, as part of a restructuring to centralize corporate functions and ...

Massive job cuts: Takeda plans to eliminate 4,500 roles in fiscal 2026, incurring over $1 billion in restructuring costs but aiming for $1.26 billion in annualized savings by 2028. Pipeline-driven ...